<DOC>
	<DOCNO>NCT02282644</DOCNO>
	<brief_summary>The recent data suggest cancer cell origin prostate cancer metastasis detect early stage . Available technique allow phenotypic analysis cancer cell circulate blood ( cellsearch ) marrow hematopoietic ( flow cytometry ) . Pilot study 180 patient infected prostate cancer stage disease , show c-met marker , integrin alpha 2 6 express marrow quantify flow cytometry predictor metastatic progress . In new study investigator analyze antibody panel cellsearch flow cytometry marrow sample castration-Resistant prostate cancer patient .</brief_summary>
	<brief_title>Individual Phenotype Analysis Patients With Castration-Resistant Prostate Cancer With CellSearch® Flow Cytometry</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate Ongoing effective androgen deprivation therapy ( testosterone ≤ 50 ng/mL ) CastrationResistant prostate cancer patient : define minimum 3 rise PSA value assess and/or radiological progress confirm RECIST PCWG2 Patient sign informed consent Severe disorder coagulation Major skin lesion iliac crest Allergies local anesthetic Psychological instability psychiatric history Uncertain followup distant residence History another invasive cancer hematologic disease Patient deprive freedom court administrative order Revocation consent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>